MedTrace Logo

Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia

NCT00947830 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2013-01-11

No results posted yet for this study

Summary

The purpose of this study is to find out if the level of imatinib in the bloodstream, and the level that leukemia cells will predict how quickly your chronic myeloid leukemia improves with the treatment.

1.1 Primary Objectives

To determine if intracellular levels of Imatinib in leukemic blood cells within two weeks of treatment initiation of patients with chronic myeloid leukemia in chronic phase predicts molecular and cytogenetic response at 6 and 12 months post treatment

1.2. Secondary Objectives

1.2.1 To determine if hOCT-1 mRNA levels at diagnosis predict Imatinib intracellular levels within two weeks of treatment initiation.

1.2.2 To determine the correlation between intracellular Imatinib levels at two weeks of treatment initiation with plasma Imatinib levels at two and four weeks after treatment initiation.

1.2.3 To determine if plasma Imatinib levels four weeks after treatment initiation correlate with plasma Imatinib levels 12 months after treatment initiation.

1.2.4 To determine if intracellular levels of Imatinib in leukemic blood cells within two weeks of treatment initiation correlate with intracellular levels of Imatinib in normal leukocytes 12 months after treatment initiation.

Conditions

  • Chronic Myeloid Leukemia

Sponsors & Collaborators

  • University Health Network, Toronto

    collaborator OTHER

  • Brian Leber

    lead OTHER

Principal Investigators

  • Brian Leber, MDCM · Hamilton Health Sciences Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00947830 on ClinicalTrials.gov